Selected data models

You must log in to select data models for download or further analysis.

12 Search results.
Relevance Rating New first Old first

Bogen 2 Adverse events DRKS00005243 NCT01657604 CML - Bogen 2 Adverse events

- 9/20/21 - 1 form, 4 itemgroups, 26 items, 2 languages
Itemgroups: Allgemeine Angaben, Unerwünschte Nebenwirkungen, SAE, Kommentar
German CML Study Group http://www.kompetenznetz-leukaemie.de/content/teilprojekte/studiengruppen/cml_projekt_7/projektleitung/index_ger.html

Adverse Event AMLSG 21-13 DRKS00007189 NCT02013648 Akute myeloische Leukämie (AML) - Adverse Event AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)

- 9/17/21 - 1 form, 3 itemgroups, 19 items, 1 language
Itemgroups: Adverse Event, Adverse Event related to, Signature
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel(TM)) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

E2905 Adverse Event Form - (CTCAE v4) NCT00843882

- 7/8/15 - 1 form, 11 itemgroups, 37 items, 1 language
Itemgroups: Header, Patient demographics, Data amendment, ON TREATMENT, OFF TREATMENT, Adverse Event Current Assessment, I. BLOOD/BONE MARROW, II. NON-HEMATOLOGIC, III. Other Adverse Events (including Infections), Other Adverse Events, Comments
E2905 Adverse Event Form - (CTCAE v4) NCT00843882 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0EAAAD8F-8F89-6BFE-E044-0003BA3F9857

E2902 Adverse Event Form - (CTCAE v3) NCT00093470

- 7/8/15 - 1 form, 7 itemgroups, 34 items, 1 language
Itemgroups: Header, Data amendment, ON TREATMENT OR OBSERVATION, OFF TREATMENT, Adverse event assessment, Other Adverse Events, Comments
E2902 Adverse Event Form - (CTCAE v3) NCT00093470 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DBCDA63A-8A39-2CC7-E034-0003BA12F5E7

CALGB: 10603 Adverse Event (AE) Form DRKS00003845 NCT00651261 - CALGB: 10603 Adverse Event (AE) Form NCT00651261

- 7/8/15 - 1 form, 4 itemgroups, 24 items, 1 language
Itemgroups: Header, Patient demographics, Adverse Drug Reaction Report, EXPECTED ADVERSE EVENTS
CALGB: 10603 Adverse Event (AE) Form NCT00651261 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=43B71921-CF4D-54F5-E044-0003BA3F9857

CALGB: 10603 Supplemental Adverse Event (AE) Form DRKS00003845 NCT00651261 - CALGB: 10603 Supplemental Adverse Event (AE) Form NCT00651261

- 6/8/15 - 1 form, 4 itemgroups, 20 items, 1 language
Itemgroups: Header, Patient demographics, Expected Adverse Events, Footer Module
CALGB: 10603 Supplemental Adverse Event (AE) Form NCT00651261 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=43B71921-D03B-54F5-E044-0003BA3F9857

Toxicity - Acute Leukemia (ALL, AML)/Myelodysplastic Syndrome (MDS) - Adverse Event Form - 2019363v3.0 - Acute Leukemia (ALL, AML)/Myelodysplastic Syndrome (MDS) - Adverse Event Form

- 1/9/15 - 1 form, 4 itemgroups, 25 items, 1 language
Itemgroups: CRF Header, ALL/AML/MDS: Form Administration, ALL/AML/MDS: Adverse Events, Comments
Acute Leukemia (ALL, AML)/Myelodysplastic Syndrome (MDS) - Adverse Event Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1A9C4726-156D-4A08-E044-0003BA3F9857

Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP Consolidation #3 and #4 Adverse Event Summary Form (S0521) - 2416199v1.0 - SOUTHWEST ONCOLOGY GROUP Consolidation #3 and #4 Adverse Event Summary Form (S0521)

- 1/9/15 - 1 form, 3 itemgroups, 17 items, 1 language
Itemgroups: Header, Adverse Events, Comments
SOUTHWEST ONCOLOGY GROUP Consolidation #3 and #4 Adverse Event Summary Form (S0521) Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=02DF0EAC-60B5-4B6D-E044-0003BA3F9857

Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP Post-Consolidation Adverse Event Summary Form: Maintenance Chemotherapy (S0521) - 2416541v1.0 - SOUTHWEST ONCOLOGY GROUP Post-Consolidation Adverse Event Summary Form: Maintenance Chemotherapy (S0521)

- 1/9/15 - 1 form, 3 itemgroups, 17 items, 1 language
Itemgroups: Header, Adverse Events, Comments
SOUTHWEST ONCOLOGY GROUP Post-Consolidation Adverse Event Summary Form: Maintenance Chemotherapy (S0521) Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=02DFCC65-BC50-09BA-E044-0003BA3F9857

Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP Induction Adverse Event Summary Form (S0521) - 2415259v1.0 - SOUTHWEST ONCOLOGY GROUP Induction Adverse Event Summary Form (S0521)

- 1/9/15 - 1 form, 3 itemgroups, 17 items, 1 language
Itemgroups: Header, Adverse Events, Comments
SOUTHWEST ONCOLOGY GROUP Induction Adverse Event Summary Form (S0521) Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=02C81B59-5981-2968-E044-0003BA3F9857

Leukemia NCT00492856 Toxicity - SOUTHWEST ONCOLOGY GROUP Consolidation #1 and #2 Adverse Event Summary Form (S0521) - 2415914v1.0 - SOUTHWEST ONCOLOGY GROUP Consolidation #1 and #2 Adverse Event Summary Form (S0521)

- 1/9/15 - 1 form, 3 itemgroups, 18 items, 1 language
Itemgroups: Header, Adverse Events, Comments
SOUTHWEST ONCOLOGY GROUP Consolidation #1 and #2 Adverse Event Summary Form (S0521) Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=02DAA575-2A50-6603-E044-0003BA3F9857

Leukemia NCT00085124 Toxicity - CALGB: 10201 ADVERSE EVENT FORM - 2070578v3.0 - CALGB: 10201 ADVERSE EVENT FORM

- 1/9/15 - 1 form, 3 itemgroups, 25 items, 1 language
Itemgroups: CALGB Form, EXPECTED ADVERSE EVENTS, CCRR MODULE
CALGB: 10201 ADVERSE EVENT FORM Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=AD846683-4685-2F05-E034-0003BA12F5E7

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial